NF-κB mediates MPP+-induced apoptotic cell death in neuroblastoma cells SH-EP1 through JNK and c-Jun/AP-1

Neurochemistry International

Volumn 56, Issue 1, 2010, Pages 128-134

  Yang, Hai Jie ^a   Wang, Lei ^a   Xia, Yin Yan ^a   Chang, Piek Ngoh ^b   Feng, Zhi Wei ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

c Jun AP 1; JNK; MPP+; NF B; SH EP1 neuroblastoma

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; 1 METHYL 4 PHENYLPYRIDINIUM; DNA BINDING PROTEIN; ENZYME INHIBITOR; HERBICIDE; I KAPPA B; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NEUROBLASTOMA CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NERVE DEGENERATION; NEUROBLASTOMA; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

1-METHYL-4-PHENYLPYRIDINIUM; ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HERBICIDES; HUMANS; I-KAPPA B PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NERVE DEGENERATION; NEUROBLASTOMA; NF-KAPPA B; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA;

EID: 73449103155     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.09.010     Document Type: Article

References (50)

1. Bian X., Opipari A.W.J., Ratanaproeksa A.B., Boitano A.E., Lucas P.C., and Castle V.P. Constitutively active NFkappa B is required for the survival of S-type neuroblastoma. J. Biol. Chem. 44 (2002) 42144-42150
2. Bouchez G., Sensebé L., Vourc'h P., Garreau L., Bodard S., Rico A., Guilloteau D., Charbord P., Besnard J.C., and Chalon S. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem. Int. 52 (2008) 1332-1342
3. Bubici C., Papa S., Dean K., and Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25 (2006) 6731-6748
4. Cassarino D.S., Halvorsen E.M., Swerdlow R.H., Abramova N.N., Parker W.D., Sturgill T.W., and Bennett J.P. Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease. J. Neurochem. 74 (2000) 1384-1392
5. Chen Y.R., and Tana T.H. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17 (1998) 173-178
6. Chen Z.J. Ubiquitin signalling in the NF-κB pathway. Nat. Cell Biol. 7 (2005) 758-765
7. Chetsawang B., Kooncumchoo P., Govitrapong P., and Ebadi M. 1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. Neurochem. Int. 53 (2008) 283-288
8. Chin P.C., Liu L., Morrison B.E., Siddiq A., Ratan R.R., Bottiglieri T., and D'Mello S.R. The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J. Neurochem. 90 (2004) 595-608
9. Dehmer T., Heneka M.T., Sastre M., Dichgans J., and Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88 (2004) 494-501
10. Deng H., Yu F., Chen J., Zhao Y., Xiang J., and Lin A. Phosphorylation of Bad at Thr-201 by JNK1 promotes glycolysis through activation of phosphofructokinase-1. J. Biol. Chem. 283 (2008) 20754-20760
11. Eberhardt O., and Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol. Lett. 139 (2003) 135-151
12. Feng Z., Li L., Ng P.Y., and Porter A.G. Neuronal differentiation and protection from nitric oxide-induced apoptosis require c-Jun-dependent expression of NCAM140. Mol. Cell Biol. 22 (2002) 5357-5366
13. Feng Z., and Porter A.G. NF-kappaB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells. J. Biol. Chem. 274 (1999) 30341-30344
14. Gearan T., Castillo O.A., and Schwarzschild M.A. The Parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures. Parkinsonism Relat. Disord. 8 (2001) 19-22
15. Halvorsen E.M., Dennis J., Keeney P., Sturgill T.W., Tuttle J.B., and Bennett Jr. J.B. Methylpyridinium (MPP(+))- and nerve growth factor-induced changes in pro- and anti-apoptotic signaling pathways in SH-SY5Y neuroblastoma cells. Brain Res. 952 (2002) 98-110
16. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., and Hirsch E.C. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 7531-7536
17. Ip Y.T., and Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development. Curr. Opin. Cell Biol. 10 (1998) 205-219
18. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 (2000) 621-663
19. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3 (2002) 221-227
20. Kim S.Y., Kim M.Y., Mo J.S., Park J.W., and Park H.S. SAG protects human neuroblastoma SH-SY5Y cells against 1-methyl-4-phenylpyridinium ion (MPP+)-induced cytotoxicity via the downregulation of ROS generation and JNK signaling. Neurosci. Lett. 413 (2007) 132-136
21. Leppä S., and Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18 (1999) 6158-6162
22. Liu J., Yang D., Minemoto Y., Leitges M., Rosner M.R., and Lin A. NF-kappaB is required for UV-induced JNK activation via induction of PKCdelta. Mol. Cell 21 (2006) 467-480
23. Malek S., Huxford T., and Ghosh G. IκBα functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-kappaB. J. Biol. Chem. 273 (1998) 25427-25435
24. Marinissen M.J., Chiariello M., Tanos T., Bernard O., Narumiya S., and Gutkind J.S. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol. Cell 14 (2004) 29-41
25. Maroney A.C., Finn J.P., Bozyczko-Coyne D., O'Kane T.M., Neff N.T., Tolkovsky A.M., Park D.S., Yan C.Y., Troy C.M., and Greene L.A. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J. Neurochem. 73 (1999) 1901-1912
26. Mora J., Cheung N.K., Juan G., Illei P., Cheung I., Akram M., Chi S., Ladanyi M., Cordon-Cardo C., and Gerald W.L. Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res. 61 (2001) 6892-6898
27. Nicotra A., and Parvez S.H. Apoptotic molecules and MPTP-induced cell death. Neurotoxicol. Teratol. 24 (2002) 599-605
28. Onyango I.G., Tuttle J.B., and Bennett J.P.J. Activation of p38 and N-acetylcysteine-sensitive c-Jun NH2-terminal kinase signaling cascades is required for induction of apoptosis in Parkinson's disease cybrids. Mol. Cell Neurosci. 28 (2005) 452-461
29. Pan J., Xiao Q., Sheng C.Y., Hong Z., Yang H.Q., Wang G., Ding J.Q., and Chen S.D. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem. Int. 54 (2009) 418-425
30. Panet H., Barzilai A., Daily D., Melamed E., and Offen D. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J. Neurochem. 77 (2001) 391-398
31. Papa S., Zazzeroni F., Bubici C., Jayawardena S., Alvarez K., Matsuda S., Nguyen D.U., Pham C.G., Nelsbach A.H., Melis T., De Smaele E., Tang W.J., D'Adamio L., and Franzoso G. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat. Cell Biol. 6 (2004) 46-53
32. Park S.H., Choi W.S., Yoon S.Y., Ahn Y.S., and Oh Y.J. Activation of NF-kappaB is involved in 6-hydroxydopamine-but not MPP+-induced dopaminergic neuronal cell death: its potential role as a survival determinant. Biochem. Biophys. Res. Commun. 322 (2004) 727-733
33. Park W.I., Park M.J., An J.K., Choi Y.H., Kim H.Y., Cheong J., and Yang U.S. Bile acid regulates c-Jun expression through the orphan nuclear receptor SHP induction in gastric cells. Biochem. Biophys. Res. Commun. 369 (2008) 437-443
34. Porcile C., Stanzione S., Piccioli P., Bajetto A., Barbero S., Bisaglia M., Bonavia R., Florio T., and Schettini G. Pyrrolidinedithiocarbamate induces apoptosis in cerebellar granule cells: involvement of AP-1 and MAP kinases. Neurochem. Int. 43 (2003) 31-38
35. Riccardi C., and Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1 (2006) 1458-1461
36. Ross R.A., Spengler B.A., and Biedler J.L. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Natl. Cancer Inst. 71 (1983) 741-747
37. + in rats. Neurochem. Int. 54 (2009) 447-451
38. Saporito M.S., Brown E.M., Miller M.S., and Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288 (1999) 421-427
39. 2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75 (2000) 1200-1208
40. Sawada H., Ibi M., Kihara T., Honda K., Nakamizo T., Kanki R., Nakanishi M., Sakka N., Akaike A., and Shimohama S. Estradiol protects dopaminergic neurons in a MPP+ Parkinson's disease model. Neuropharmacology 42 (2002) 1056-1064
41. Singh S., and Aggarwal B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 270 (1995) 24995-25000
42. Soos J., Engelhardt J.I., Siklos L., Havas L., and Majtenyi K. The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. Neuroreport 15 (2004) 1715-1718
43. Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F.F., Yantiri F., Yang L., Beal M.F., and Andersen J.K. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. 21 (2001) 9519-9528
44. Wang W., Ma C., Mao Z., and Li M. JNK inhibition as a potential strategy in treating Parkinson's disease. Drug News Perspect. 17 (2004) 646-654
45. Wei P., Inamdar N., and Vedeckis W.V. Transrepression of c-jun gene expression by the glucocorticoid receptor requires both AP-1 sites in the c-jun promoter. Mol. Endocrinol. 12 (1998) 1322-1333
46. Wong C., Rougier-Chapman E.M., Frederick J.P., Datto M.B., Liberati N.T., Li J.M., and Wang X.F. Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta. Mol. Cell Biol. 19 (1999) 1821-1830
47. Xia X.G., Harding T., Weller M., Bieneman A., Uney J.B., and Schulz J.B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10433-10438
48. Yang H., Magilnick N., Ou X., and Lu S.C. Tumour necrosis factor alpha induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor kappaB and activator protein-1. Biochem. J. 391 (2005) 399-408
49. Yu Z., Zhou D., Bruce-Keller A.J., Kindy M.S., and Mattson M.P. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J. Neurosci. 19 (1999) 8856-8865
50. Yuan Y., Jin J., Yang B., Zhang W., Hu J., Zhang Y., and Chen N.H. Overexpressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway. Cell Mol. Neurobiol. 28 (2008) 21-33